首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.

【24h】

EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.

机译：在一项晚期非小细胞肺癌患者二线治疗的随机III期研究中，EGFR生物标记物预测了Vandetanib与docetaxel联用的益处。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

NCT00312377.

机译：巢00312377。

著录项

来源
《Annals of oncology: official journal of the European Society for Medical Oncology》 |2014年第10期|共8页
作者
J V Heymach; S J Lockwood; R S Herbst; B E Johnson; A J Ryan;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. CMAB009联合伊立替康或伊立替康单药二线治疗氟嘧啶和奥沙利铂治疗失败的KRAS野生型转移性结直肠癌患者的研究:一项前瞻性、开放、随机、Ⅲ期试验 [J] . 石远凯, 白丽, 张沂平, 癌症（英文版） . 2020,第007期
2. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer. [J] . J V Heymach, S J Lockwood, R S Herbst, Annals of oncology: official journal of the European Society for Medical Oncology . 2014,第10期

机译：在一项晚期非小细胞肺癌患者二线治疗的随机III期研究中，EGFR生物标记物预测了Vandetanib与docetaxel联用的益处。
3. 9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial [J] . W.E.E.Eberhardt, B.E.Johnson, Y.Sun, European Journal of Cancer Supplements . 2009,第2期

机译：9001 Vandetanib联合多西他赛与多西他赛作为晚期非小细胞肺癌（NSCLC）患者的二线治疗：一项随机，双盲III期临床试验
4. 9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial [J] . W.E.E.Eberhardt, B.E.Johnson, Y.Sun, European Journal of Cancer Supplements . 2009,第2期

机译：9001 Vandetanib联合多西他赛与多西他赛作为晚期非小细胞肺癌（NSCLC）患者的二线治疗：一项随机，双盲III期临床试验
5. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
6. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
7. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer [O] . J. V. Heymach, S. J. Lockwood, R. S. Herbst, -1

机译：EGFR生物标志物预测Vandetanib联合多西他赛可从晚期非小细胞肺癌二线治疗的随机III期研究中获益
8. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer [O] . J.V. Heymach, S.J. Lockwood, R.S. Herbst, 2014

机译：EGFR Biomarkers预测Vandetanib的益处与多西紫杉醇组合在随机的非小细胞肺癌患者的二线治疗的随机期III研究中

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号